Neurocrine Biosciences
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric condi...
Latest News
14 hours ago · zacks.com
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
6 days ago · zacks.com
NBIX or GRDN: Which Is the Better Value Stock Right Now?Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks presents investors with the better value opportunity right now?
7 days ago · zacks.com
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid ChoiceNeurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
8 days ago · zacks.com
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to BuyNeurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
8 days ago · zacks.com
NBIX vs. GRDN: Which Stock Is the Better Value Option?Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX) or Guardian Pharmacy Services (GRDN). But which of these two companies is the best option for those looking for undervalued stocks?
8 days ago · zacks.com
Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Neurocrine (NBIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
12 days ago · prnewswire.com
Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) CapsulesSurvey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from 5.6 to 2.0 A separate post-hoc analysis of KINECT-PRO™ data showed patient-reported improvement with INGREZZA across all six physical and socio-emotional areas assessed by the Tardive Dyskinesia Impact Scale (TDIS™) among participants reporting impacts to those areas at baseline SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey showing that adults with tardive dyskinesia (TD) reported fewer disruptions to work and school after starting treatment with INGREZZA® (valbenazine) capsules.1 A separate post-hoc analysis of the KINECT-PRO™ Phase 4 open-label study showed robust patient-reported improvement with INGREZZA across all six physical and socio-emotional areas measured by the Tardive Dyskinesia Impact Scale (TDIS™) among participants who reported impacts in those areas at baseline. The TDIS is the only psychometrically validated tool that measures the burden of TD from a patient's perspective.
12 days ago · seekingalpha.com
Neurocrine Biosciences: Breaking Down A Solid QuarterNeurocrine Biosciences delivered robust Q3 results Monday after the bell, with EPS of $3.29 and revenue up 41% to $1.12 billion. INGREZZA remains NBIX's primary growth driver, posting 17% year-over-year sales growth to $801 million on strong volume gains. The Soleno Therapeutics acquisition and VYKAT XR approval expand NBIX's rare disease portfolio, with VYKAT XR showing strong initial adoption.
13 days ago · seekingalpha.com
Neurocrine Biosciences: 3 Growth Drivers And An Attractive ValuationNeurocrine Biosciences is in an attractive growth phase, driven by strong INGREZZA sales and rapid expansion of CRENESSITY and VYKAT XR. Q3 2026 revenue grew 41% year-over-year to $1.123 billion, reflecting increasing product diversification and reduced dependency on INGREZZA. NBIX trades at a forward P/E of 14.19x, below sector peers, with declining multiples and robust adjusted profitability supporting a buy rating.
13 days ago · seekingalpha.com
Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost FreeNeurocrine Biosciences is reiterated as a buy with a new fair value of $195.80, 19% above the recent price. The investment thesis centers on NBIX's underappreciated early research engine, now valued using an industry productivity rate, materially lifting fair value. Q3 results exceeded expectations: INGREZZA and CRENESSITY both outperformed, but VYKAT XR faces ongoing safety and patent risks.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NBIX